Atorvastatin (sodium)

Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3][4][5].

Product Specifications

CAS Number

[134523-01-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; HMG-CoA Reductase (HMGCR)

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/atorvastatin-sodium.html

Purity

99.85

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(C(C)C)N(CC[C@H](O)C[C@H](O)CC(O[Na])=O)C(C2=CC=C(F)C=C2)=C1C3=CC=CC=C3)NC4=CC=CC=C4

Molecular Formula

C33H34FN2NaO5

Molecular Weight

580.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Br J Pharmacol. 2006 Sep;149 (1) :14-22.|[2]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50 (4) :458-61.|[3]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15 (5) : p. 678-82.|[4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8 (7) :564-72.|[5]Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12 (4) :e0174821.|[6]Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42 (5) :409-415.